Sen. Grassley Considering Tighter Securities Laws To Prevent Clinical Trial Disclosure
This article was originally published in The Pink Sheet Daily
Executive Summary
Letter to the Department of Justice and the Securities & Exchange Commission requests an investigation into allegations of insider trading.
You may also be interested in...
Sen. Grassley Requests OIG Review Of Clinical Trial Oversight
A letter to OIG asks whether "administrative, regulatory, and/or legislative corrective actions in this area are needed."
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.